{
  "slug": "addiction-brain-disease",
  "round": 2,
  "group": 12,
  "date": "2026-10-14",
  "authoring_model": "Sol 6.1",
  "adversarial_reviewer": "Claude Opus 5.5 (Anthropic)",
  "canonical_path": "consensus_consistency_audit_2026-10-09/revised/addiction-brain-disease/addiction-brain-disease.review.md",
  "edition_note": "Revised edition carrying the 9 October 2026 Consensus consistency validation block; reviewed as it now stands.",
  "divergent_copies_not_touched": [
    "hsef_v53_remaining_priority_01_05_2026-10-09/addiction-brain-disease/addiction-brain-disease.review.md"
  ],
  "level_before": "Γ",
  "level_after": "Γ",
  "confidence_before": "Moderate",
  "confidence_after": "Moderate",
  "role_before": "reinforcing / stabilizing factor",
  "role_after": "reinforcing / stabilizing factor",
  "pmids_checked": 59,
  "pmids_checked_note": "56 reference-list PMIDs plus the 3 supplemental PMIDs introduced by the 9 October validation block",
  "pmids_failed": 0,
  "retractions_or_eoc_found": 0,
  "claims_spot_checked": 12,
  "validator": {
    "before": "PASS — 0 fail, 0 warn, 30 pass",
    "after": "PASS — 0 fail, 0 warn, 30 pass (identical)"
  },
  "findings": [
    {
      "id": "AR-1",
      "severity": "Major",
      "type": "revision_regression_reviewer_notes_contradiction",
      "location": ["REVIEWER NOTES, first paragraph"],
      "original": "No independent blind grading, Consensus, Scite or independent scientific peer review was performed.",
      "corrected": "The same sentence scoped to the original 2026-10-09 review pass, followed by a clause recording that the dated Consensus consistency validation above is a later, separately scoped supplement that changed no grade and is not blind calibration either because the prior score was visible to it.",
      "evidence": "The known systematic artifact, present in this case. The 9 October integration spliced in a Consensus consistency validation section documenting a raw Consensus Pro and browser response, connector-search discovery leads and cited Consensus markers [19.1] and [19.2], while leaving the preserved REVIEWER NOTES sentence denying that any Consensus work was performed. Repaired by scoping the original sentence rather than deleting either block.",
      "level_impact": "none"
    },
    {
      "id": "AR-2",
      "severity": "Major",
      "type": "revision_regression_false_approval_boilerplate",
      "location": ["closing paragraph of the validation block in the review", "consensus-addendum.md"],
      "original": "Its original narrative, registered scope, source inventory, grades and any earlier approval remain historical records; the earlier approval does not certify this supplement.",
      "corrected": "Its original narrative, registered scope, source inventory and grades remain historical records. No earlier adversarial approval is attached to this case, and nothing in the record certifies this supplement.",
      "evidence": "The second clause presupposes an earlier approval although the first hedges it. The earlier edition at hsef_v53_remaining_priority_01_05_2026-10-09/addiction-brain-disease/ contains no ADVERSARIAL REVIEW AND APPROVAL section and no adversarial banner.",
      "level_impact": "none"
    },
    {
      "id": "AR-3",
      "severity": "Minor",
      "type": "revision_regression_broken_table",
      "location": ["Primary-source checks table inside the validation block"],
      "original": "Three rows without a trailing cell delimiter, and the fourth row separated from the table by two blank lines so that it rendered as a detached header-less one-row table.",
      "corrected": "Trailing delimiters added, the two blank lines removed so the fourth row rejoins the table, and a blank line inserted before the following heading. Row content unchanged.",
      "evidence": "Revision-introduced rendering defect: the row added for the Rewarding Recovery trial was appended after a paragraph break."
    },
    {
      "id": "AR-4",
      "severity": "Minor",
      "type": "confidence_justified_by_access_depth",
      "location": ["scorecard final_score.confidence_rationale and its two duplicates"],
      "original": "56 primary reports with 2 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness.",
      "corrected": "Rationale restated on evidence-density and reproducibility grounds, naming the review's own documented reservations and explicitly excluding the reviewer's access depth.",
      "evidence": "Lead two-step test (2026-10-14). Step 1: access depth struck as a determinant. Step 2: band re-derived and retained at Moderate, because the review documents substantive evidence-quality reservations - the causal results are rodent behavioural proxies, the human neural evidence is associational or predictive rather than a mediator manipulation, severity selection and mortality confound treated-versus-untreated comparisons, and course heterogeneity is marked. These are legitimate determinants, so the High text is not met.",
      "level_impact": "none; band unchanged at Moderate"
    },
    {
      "id": "AR-5",
      "severity": "Minor",
      "type": "missing_required_artifact",
      "location": ["Final score block, Divergence line", "scorecard extended_scoring_MSD.divergence.justification"],
      "original": "Contested; no single implied-level arithmetic. No manufactured field consensus or arithmetic gap.",
      "corrected": "Same value, now naming the split: public-health and research framing of addiction as a chronic relapsing brain disease with compromised volition against the choice and natural-recovery reading of the same incentive and course data (PMID27442691,33220122,8271810).",
      "evidence": "Divergence is computed, not felt; Contested requires showing a genuine split. Both prose and score card previously asserted only the absence of an arithmetic gap."
    },
    {
      "id": "AR-6",
      "severity": "Editorial",
      "type": "rendering_defect",
      "location": ["Reference 3 (PMID 21266151)", "momentum artifact in the review and the score card"],
      "original": "DOI: . ; (PMIDs34407947,32273471) ; (PMIDs42522065,42070571)",
      "corrected": "DOI: not available. ; (PMID34407947,32273471) ; (PMID42522065,42070571)",
      "evidence": "Builder rendering defects. PubMed supplies no DOI for PMID 21266151, so only the empty field needed repair; the plural label was fused to the first identifier and is inconsistent with the house citation style used throughout the document."
    }
  ],
  "rejected_findings": [
    {
      "id": "RJ-1",
      "claim": "The headline should be Delta or Beta.",
      "resolution": "Rejected both. Primary-subclaim is pre-registered and applied as written: SC3 carries the website claim at its stated scope and its Gamma sets the headline, with SC1 and SC2 reported without gating. All three alternatives are reported and coincide at Gamma, so rule-shopping is impossible here. Delta fails because nothing manipulates a proposed endogenous human adaptation while preserving the drug effect and measures an objective trajectory across a prespecified general substance-use-disorder scope. Beta fails because the amygdala GAT-3, PKC-delta ensemble and optogenetic dopamine experiments are genuine causal perturbations."
    },
    {
      "id": "RJ-2",
      "claim": "Scope-matched aggregation is misread.",
      "resolution": "Rejected; checked and absent. The headline is set by the primary subclaim, and the scope-restricted model results stay at SC2 rather than being promoted to carry the general human claim."
    },
    {
      "id": "RJ-3",
      "claim": "'Best-supported rival' prints the nominal model (the renderer bug reported elsewhere this round).",
      "resolution": "Rejected; checked and absent. models_evaluated[0] is is_nominal false at rank 1 (Context-dependent neurobehavioral disorder); the nominal (Persistent-neuroadaptation primacy) sits at rank 2."
    },
    {
      "id": "RJ-4",
      "claim": "Momentum is boilerplate.",
      "resolution": "Rejected. The value is already 'Mechanistic only' and correctly so: the artifact names real work (targeted rodent studies, the 2026 alcohol-use-disorder semaglutide trials) and states that no selective human mediator trial of general volitional incapacity was identified."
    },
    {
      "id": "RJ-5",
      "claim": "The causal role is wrong.",
      "resolution": "Rejected. 'reinforcing / stabilizing factor' follows the derivation procedure, which the review walks through step by step and which lands at step 5; the prose correctly refuses primary driver because general human initiation, rate limitation and universal necessity are not established."
    },
    {
      "id": "RJ-6",
      "claim": "The four source-level rows added by the revision misstate their sources.",
      "resolution": "Rejected; all four verified accurate against PubMed abstracts. 35697842: cohorts of 67 and 62 plus an independent 186-patient alcohol-risk cohort, with the authors' own candidate-target framing. 37567334: 68 patients and 42 controls, 27 abstinent and 33 relapsed at six months. 27442691: 65-person trial randomized 33 and 32, denominator distinction preserved. 33220122: 114 American Indian adults in a 2x2 factorial trial, alcohol-abstinent odds ratios 2.4 to 4.8, drug contrasts losing significance under multiple imputation, reported with the abstract's own word 'inconclusive'. Supplemental sources are correctly excluded from the 56-source inventory and the double-counting warning is correct."
    },
    {
      "id": "RJ-7",
      "claim": "The semaglutide claims are overstated.",
      "resolution": "Rejected; checked against both 2026 trials. The oral trial missed its primary craving endpoint and drinks per day while reducing heavy drinking days, and the once-weekly trial is confined to patients with comorbid obesity. The review's phrasing is accurate."
    },
    {
      "id": "RJ-8",
      "claim": "Reference years disagree with PubMed.",
      "resolution": "Rejected per convention. References 4, 12, 14, 26, 27, 28, 29, 32, 43 and 54 differ from the PubMed e-pub year by one."
    },
    {
      "id": "RJ-9",
      "claim": "Collective-author defect, 'PMIDnot supplied' or other fused numeral tokens present.",
      "resolution": "Rejected; screened across all 56 references, the timeline and the evidence cards and none present beyond the two label fusions corrected in AR-6."
    }
  ],
  "residual_limitations": "Only two originals were read at partial-body depth, so Methods-level detail elsewhere rests on bounded abstract and status records, as the review states; the Joutsa voxel-based lesion-symptom-mapping non-significance and the MacNiven 72.7 percent cross-validated accuracy come from figure captions and the abstract rather than the full Results. The raw Consensus browser response referred to in the validation block was not available to this reviewer, so its provenance claims were checked only for internal consistency against the review's own statements.",
  "propagation_strings_for_lead": [],
  "approval": "Approved as revised. — Claude Opus 5.5 (Anthropic), 2026-10-14."
}